Diligence memo · auto-generated · as of July 2, 2026
OriGene Technologies, Inc.
OriGene Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
OriGene Technologies, Inc. operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
OriGene Technologies, Inc. has raised $39M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $17M on 2015-05-26.
Most recent recorded round closed around 2015-05-26.
Valuation (modeled)modeled
Provath models OriGene Technologies, Inc. at approximately $677M (range $34M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.95× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 11.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 85.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4293 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.